ClinicalTrials.gg
Active, not recruitingNCT06602193Updated May 27, 2026

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

A Phase 2 interventional study of BIIB122 225 mg and BIIB122-Matching Placebo in Parkinson Disease, sponsored by Denali Therapeutics Inc.. Active, not recruiting at 20 sites in 4 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Denali Therapeutics Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
480th of 1,257
50 · median 36
Started
2024
with 80 others
Phase 2
234 of 1,650
25 open now
Primary completion
2027-03
later than 141 of 384 live
Registered
1,472nd of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 480th largest by planned enrollment of the 1,257 interventional ones that give a count, is one of 81 that started in 2024, is one of 234 in phase 2, reaches primary completion later than 141 of the 384 other live ones, and was the 1,472nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.

03

Conditions studied

  • Parkinson Disease

Keywords

  • LRRK2
  • Movement Disorders
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For heterozygous pathogenic LRRK2 mutation carriers: ≥ 30 to ≤ 80 years
  • For homozygous pathogenic LRRK2 mutation carriers: ≥ 30 years
  • Have screening genetic test results verifying the presence of a pathogenic LRRK2 variant.
  • Have a clinical diagnosis of PD meeting the Movement Disorder Society Clinical Diagnostic Criteria.

Exclusion criteria

Exclusion Criteria:

  • Have a history of any neurological disorder other than PD, including, but not limited to, stroke and dementia, in the opinion of the investigator, within 5 years of the screening visit.
  • Have clinical evidence of atypical parkinsonism (eg, multiple-system atrophy or progressive supranuclear palsy) or evidence of drug-induced parkinsonism.
  • Have previously participated or are currently participating in the BIIB122 LUMA study (Study 283PD201).
  • Have previously participated or are currently participating in a gene therapy study for PD.
  • Have a history of brain surgical intervention for PD (eg, deep-brain stimulation, pallidotomy).
  • Have any physical condition that may confound the motor assessment (MDS-UPDRS) over time (eg, severe arthritis, severe dyskinesias, traumatic injuries with permanent physical disability).
  • Abnormal vitals including Blood Pressure, Heart Rate, or Body Temperature
  • Have abnormal PFT results at screening

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    BIIB122 225 mg

    Oral 225 mg dose, once daily (QD)

    Drug: BIIB122 225 mg

  • Placebo comparator
    BIIB122 Matching Placebo

    Oral BIIB122 matching placebo, once daily (QD)

    Other: BIIB122-Matching Placebo

Interventions

  • DrugDNL151Studies of DNL151DNL151 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered as specified in the treatment arm

    Also known as: DNL151

  • OtherBIIB122-Matching Placebo

    Administered as specified in the treatment arm

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) with BIIB122 compared with placebo over the 12-week double-blind period

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline in whole-blood pS935 LRRK2 with BIIB122 compared with placebo at Week 12

    Time frame: 12 weeks

  2. Change from baseline in urine BMP with BIIB122 compared with placebo at Week 12

    Time frame: 12 weeks

Other outcomes

  1. Incidence of TEAEs and SAEs during the OLE period

    Time frame: 2.5 years

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Mar 2027, 29 months after the start.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 29 months is above that.

Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2024
First posted
Sep 19, 2024
StartActual
Oct 24, 2024
Primary completionEst.
Mar 2027
CompletionEst.
Feb 28, 2028
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06602193
Lead sponsor
Denali Therapeutics Inc.
Collaborators
Biogen
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 24, 2024
Primary completion
Mar 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
May 27, 2026

Study contacts

Danna Jennings, MD
study director · Denali Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DNL151

Start the discussion